Recent developments
Demand and pricing
Personal care exposure showed mixed fundamentals: Clariant Q1 2026 posted slight Care Chemicals volume gains amid lower prices; Symrise Q1 2026 saw UV filter weakness and stable fragrances; Croda Q1 2026 sales grew in Beauty Actives and F&F. Packaging demand improved at Aptar Q1 2026 results, while macro and FX pressured BASF Q1 2026 and Dow Q1 2026 results.
Aroma and inputs
BASF commissions world‑scale menthol and linalool plants and a citral unit, expanding aroma supply integrated with Verbund assets. Upstream processing for beauty and pharma will tighten specs as the specialty hydrogen peroxide plant in Leshan starts trial production. Fermentation capabilities broaden with Evonik’s expands biotech drug‑substance capacity in Slovakia, supporting biosurfactants and actives.
Formulation innovation
Croda introduced the Matrixyl Neolide controlled‑release peptide to stabilize delivery and reduce formulation complexity. Access to advanced actives widens as Brenntag distributes Shinehigh’s supramolecular active ingredients across key regions. Circular packaging options advanced with PureCycle’s A3 CosPaTox designation for leave‑on cosmetic‑grade polypropylene.
Portfolio and leadership
Portfolio focus continued as dsm‑firmenich sells Action Pin, streamlining its Perfumery & Beauty scope. In silicones, Momentive names Bob Waitt CCO to drive commercial strategy in end‑markets that include personal care.
Outlook and risks
Companies maintained cautious outlooks, noting order delays tied to regional conflict and currency effects. BASF Q1 2026 reaffirmed guidance while flagging oil‑price sensitivity. Clariant Q1 2026 cited logistics mitigation and EU approval for renewable Licocare rice bran wax in food‑contact plastics, alongside lower Scope 1‑2 emissions.